## Mauro Alaibac

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/729352/publications.pdf

Version: 2024-02-01

152 papers 2,439 citations

279798 23 h-index 254184 43 g-index

156 all docs

156 docs citations

156 times ranked 3205 citing authors

#	Article	IF	CITATIONS
1	Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo, 2014, 28, 1005-11.	1.3	269
2	Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas. Journal of Clinical Oncology, 2006, 24, 1376-1382.	1.6	199
3	Skin cancer in heart transplant recipients: frequency and risk factor analysis. Journal of Heart and Lung Transplantation, 2000, 19, 249-255.	0.6	121
4	Immunosuppressive Level and Other Risk Factors for Basal Cell Carcinoma and Squamous Cell Carcinoma in Heart Transplant Recipients. Archives of Dermatology, 2004, 140, 1079-85.	1.4	105
5	Time course, clinical pathways, and longâ€term hazards risk trends of disease progression in patients with classic mycosis fungoides. Cancer, 2012, 118, 5830-5839.	4.1	105
6	Electrochemotherapy of superficial tumors – Current status:. Seminars in Oncology, 2019, 46, 173-191.	2.2	80
7	Eruptive melanocytic nevi in patients with renal allografts: Report of 10 cases with dermoscopic findings. Journal of the American Academy of Dermatology, 2003, 49, 1020-1022.	1.2	65
8	Immunosuppression and melanocyte proliferation. Melanoma Research, 2009, 19, 63-68.	1.2	61
9	Bullous Pemphigoid during Long-Term TNF-α Blocker Therapy. Dermatology, 2009, 219, 357-358.	2.1	56
10	Detection of Autoantibodies against Recombinant Desmoglein 1 and 3 Molecules in Patients with Pemphigus vulgaris: Correlation with Disease Extent at the Time of Diagnosis and during Follow-Up. Clinical and Developmental Immunology, 2009, 2009, 1-6.	3.3	54
11	Basal cell carcinoma: 10-year experience with electrochemotherapy. Journal of Translational Medicine, 2017, 15, 122.	4.4	46
12	Sunscreen tests: Correspondence between in vitro data and values reported by the manufacturers. Journal of Dermatological Science, 2008, 52, 193-204.	1.9	36
13	Skin Cancer and Other Cutaneous Disorders in Liver Transplant Recipients. Acta Dermato-Venereologica, 2012, 92, 411-415.	1.3	34
14	Primary cutaneous Bâ€cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. Cancer Medicine, 2016, 5, 2740-2755.	2.8	34
15	Clinical and dermatoscopic fading of post-transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy. Journal of the American Academy of Dermatology, 2006, 54, 338-340.	1.2	30
16	Biochip Technology for the Serological Diagnosis of Bullous Pemphigoid. ISRN Dermatology, 2012, 2012, 1-4.	1.9	30
17	Increased risk of venous thromboembolism in patients with bullous pemphigoid. Thrombosis and Haemostasis, 2016, 115, 193-199.	3.4	30
18	Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. Experimental Dermatology, 2006, 15, 958-965.	2.9	29

#	Article	IF	CITATIONS
19	The use of biochip immunofluorescence microscopy for the diagnosis of Pemphigus vulgaris. Acta Histochemica, 2014, 116, 713-716.	1.8	29
20	C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. Transplant International, 2005, 18, 116-124.	1.6	27
21	High-dose chemotherapy with autologous blood stem cell transplantation for aggressive subcutaneous panniculitis-like T-cell lymphoma. Journal of the American Academy of Dermatology, 2005, 52, S121-S123.	1.2	27
22	Effectiveness of different substrate materials for in vitro sunscreen tests. Journal of Dermatological Science, 2009, 56, 89-98.	1.9	27
23	Vohwinkel syndrome: treatment of pseudoâ€einhum. International Journal of Dermatology, 2010, 49, 79-82.	1.0	26
24	Expression of the CD1a molecule in B- and T-lymphoproliferative skin conditions. Oncology Reports, 2006, 15, 347-51.	2.6	24
25	Facial basal cell carcinoma: Analysis of recurrence and follow-up strategies. Oncology Reports, 2011, 26, 1423-9.	2.6	22
26	Vitamins and Melanoma. Cancers, 2015, 7, 1371-1387.	3.7	22
27	Cutaneous squamous cell carcinoma. Italian Guidelines by SIDeMaST adapted to and updating EADO/EDF/EORTC guidelines. Giornale Italiano Di Dermatologia E Venereologia, 2018, 153, 747-762.	0.8	22
28	Subcorneal Pustular Dermatosis (Sneddon-Wilkinson Disease) with Absence of Desmoglein 1 and 3 Antibodies. American Journal of Clinical Dermatology, 2008, 9, 51-55.	6.7	21
29	The use of Biochip immunofluorescence microscopy for the serological diagnosis of epidermolysis bullosa acquisita. Archives of Dermatological Research, 2016, 308, 273-276.	1.9	20
30	CD7 expression in reactive and malignant human skin T-lymphocytes. Anticancer Research, 2003, 23, 2707-10.	1.1	20
31	Bullous pemphigoid: An immune disorder related to aging (Review). Experimental and Therapeutic Medicine, 2021, 23, 50.	1.8	19
32	Dermoscopic features of eruptive melanocytic naevi in an adult patient receiving immunosuppressive therapy for Crohn??s disease. Melanoma Research, 2005, 15, 223-224.	1.2	18
33	Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab. European Journal of Dermatology, 2017, 27, 205-208.	0.6	18
34	Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions. Frontiers in Immunology, 2018, 9, 810.	4.8	18
35	Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study. Expert Opinion on Biological Therapy, 2020, 20, 673-678.	3.1	18
36	Purification of Functional Active Epidermal Langerhans Cells: A Simple and Efficient New Technique. Journal of Investigative Dermatology, 1992, 99, 237-240.	0.7	17

#	Article	IF	CITATIONS
37	Skin disorders in patients transplanted in childhood. Transplant International, 2005, 18, 360-365.	1.6	17
38	Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients. Cancers, 2018, 10, 350.	3.7	17
39	Primary Cutaneous Mantle Cell Lymphoma. Acta Dermato-Venereologica, 2011, 91, 474-475.	1.3	16
40	Erosive Pustular Dermatosis of the Scalp Induced by Imiquimod. Case Reports in Dermatological Medicine, 2012, 2012, 1-2.	0.3	16
41	Evaluation of anti-desmoglein-1 and anti-desmoglein-3 autoantibody titers in pemphigus patients at the time of the initial diagnosis and after clinical remission. Medicine (United States), 2017, 96, e8801.	1.0	16
42	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. The Lancet Child and Adolescent Health, 2019, 3, 332-342.	5.6	16
43	Melanoma in skin affected with keratoderma palmoplantaris hereditaria (Mal de Meleda): Treatment with excision and grafting. Journal of the American Academy of Dermatology, 2009, 61, 161-163.	1.2	15
44	Nevus Spilus and Melanoma: Case Report and Review of the Literature. Journal of Cutaneous Medicine and Surgery, 2010, 14, 85-89.	1.2	15
45	Large plaque type blue nevus withÂsubcutaneous cellular nodules. European Journal of Dermatology, 2009, 19, 287-287.	0.6	15
46	Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma. Scientifica, 2018, 2018, 1-7.	1.7	14
47	Management of melanoma patients during COVIDâ€19 pandemic in an Italian skin unit. Dermatologic Therapy, 2021, 34, e14908.	1.7	14
48	Functional defect in cells involved in Langerhans cell histiocytosis. Archives of Dermatological Research, 1995, 287, 627-631.	1.9	13
49	Two-years of home based functional electrical stimulation recovers epidermis from atrophy and flattening after years of complete Conus-Cauda Syndrome. Medicine (United States), 2019, 98, e18509.	1.0	13
50	Incidence and clinical predictors of primary opportunistic deep cutaneous mycoses in solid organ transplant recipients: a multicenter cohort study. Clinical Transplantation, 2010, 24, 328-333.	1.6	12
51	Erythroderma in the era of biological therapies. European Journal of Dermatology, 2012, 22, 167-171.	0.6	12
52	Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera. In Vivo, 2019, 33, 1667-1669.	1.3	12
53	Melanoma m1: diagnosis and therapy. In Vivo, 2014, 28, 273-85.	1.3	12
54	Imiquimod for the Treatment of Classical Kaposi's Sarcoma. Acta Dermato-Venereologica, 2010, 90, 417-418.	1.3	11

#	Article	IF	CITATIONS
55	Adaptive Immune Responses in Primary Cutaneous Sarcoidosis. Clinical and Developmental Immunology, 2011, 2011, 1-6.	3.3	11
56	Female Patients with Dermatitis Herpetiformis Show a Reduced Diagnostic Delay and Have Higher Sensitivity Rates at Autoantibody Testing for Celiac Disease. BioMed Research International, 2019, 2019, 1-7.	1.9	11
57	?? T-LYMPHOCYTES: RELEVANCE OF THE CURRENT STUDIES TO DERMATOLOGY. International Journal of Dermatology, 1992, 31, 157-159.	1.0	10
58	Bullous Scabies Simulating Pemphigoid. Journal of Cutaneous Medicine and Surgery, 2011, 15, 55-57.	1.2	10
59	Melanoma M (Zero): Diagnosis and Therapy. ISRN Dermatology, 2013, 2013, 1-10.	1.9	10
60	TLR7 Gln11Leu single nucleotide polymorphism and response to treatment with imiquimod in patients with basal cell carcinoma: a pilot study. Pharmacogenomics, 2015, 16, 1913-1917.	1.3	10
61	Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases. Journal of Translational Medicine, 2017, 15, 227.	4.4	10
62	A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience. European Journal of Dermatology, 2017, 27, 482-486.	0.6	10
63	Association between Toll-like receptor 7 Gln11Leu single-nucleotide polymorphism and basal cell carcinoma. Biomedical Reports, 2016, 4, 459-462.	2.0	9
64	<i>Citrobacter freundii</i> sepsis in an immunosuppressed patient with pemphigus vulgaris. BMJ Case Reports, 2018, 11, e227091.	0.5	9
65	Salivary Samples for the Diagnosis of Pemphigus vulgaris Using the BIOCHIP Approach: a Pilot Study. In Vivo, 2017, 31, 97-100.	1.3	9
66	Acne Keloidalis of the Scalp in a Renal Transplant Patient Treated with Cyclosporine. Acta Dermato-Venereologica, 2009, 89, 312-313.	1.3	8
67	The role of immunohistochemical analysis in the diagnosis of parapsoriasis. Acta Histochemica, 2011, 113, 92-95.	1.8	8
68	Successful treatment of pyoderma gangrenosum with granulocyte and monocyte adsorption apheresis. International Wound Journal, 2017, 14, 282-284.	2.9	8
69	Biological Approaches to Aggressive Cutaneous B-Cell Lymphomas. Frontiers in Oncology, 2019, 9, 1238.	2.8	8
70	Near infrared photoimmunotherapy targeting the cutaneous lymphocyte antigen for mycosis fungoides. Expert Opinion on Biological Therapy, 2020, 21, 1-5.	3.1	8
71	Targeting the cutaneous lymphocyte antigen (CLA) in inflammatory and neoplastic skin conditions. Expert Opinion on Biological Therapy, 2020, 20, 275-282.	3.1	8
72	A Therapeutic and Diagnostic Multidisciplinary Pathway for Merkel Cell Carcinoma Patients. Frontiers in Oncology, 2020, 10, 529.	2.8	8

#	Article	IF	Citations
73	Epidermolysis bullosa acquisita in a 17-year-old boy with Crohn's disease. BMJ Case Reports, 2015, 2015, bcr2015210210.	0.5	8
74	T-Lymphocytes bearing the $\hat{l}^3\hat{l}$ T-cell receptor in cutaneous lesions of langerhans' cell histiocytosis. Medical and Pediatric Oncology, 1993, 21, 347-349.	1.0	7
75	The Expression Pattern of the AML1 Gene in Non-Hodgkin's B-Cell Lymphomas and Normal B Lymphocytes. Blood Cells, Molecules, and Diseases, 2000, 26, 186-192.	1.4	7
76	Porokeratosis ptychotropica. European Journal of Dermatology, 2011, 21, 416-417.	0.6	7
77	Occurrence of Squamous Cell Carcinoma in an Area of Lichen Simplex Chronicus: Case Report and Pathogenetic Hypothesis. Journal of Cutaneous Medicine and Surgery, 2012, 16, 350-352.	1.2	7
78	Role of alpha5beta1 integrin and MIA (melanoma inhibitory activity) in the pathogenesis of vitiligo. Journal of Dermatological Science, 2013, 71, 142-145.	1.9	7
79	Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature. Experimental and Therapeutic Medicine, 2016, 11, 197-200.	1.8	7
80	Biological therapy of autoimmune blistering diseases. Expert Opinion on Biological Therapy, 2019, 19, 149-156.	3.1	7
81	Use of granulocyte and monocyte adsorption apheresis in dermatology (Review). Experimental and Therapeutic Medicine, 2022, 24, .	1.8	7
82	Angioimmunoblastic lymphadenopathy with dysproteinemia and dermal T-cell lymphoma. Cancer, 1994, 74, 1801-1807.	4.1	6
83	Primary Subcutaneous B-cell Lymphoma: Case Report and Literature Review. Acta Dermato-Venereologica, 2008, 88, 151-154.	1.3	6
84	Non-alcoholic fatty liver disease, alcohol intake and psoriasis. Journal of Hepatology, 2010, 53, 587.	3.7	6
85	Achromic Superficial Spreading Melanoma Accidentally Treated with Imiquimod. Acta Dermato-Venereologica, 2012, 92, 107-108.	1.3	6
86	TLR7 Gln11Leu single nucleotide polymorphism and susceptibility to cutaneous melanoma. Oncology Letters, 2016, 12, 275-280.	1.8	6
87	Monoclonal antibodies against cutaneous T-cell lymphomas. Expert Opinion on Biological Therapy, 2017, 17, 1503-1510.	3.1	6
88	Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143). Frontiers in Oncology, 2021, 11, 737842.	2.8	6
89	An unusual association between erosive hand osteoarthritis and morphea. Joint Bone Spine, 2011, 78, 532-533.	1.6	5
90	A case of psoriasis pustolosa palmaris induced by cetuximab. BMJ Case Reports, 2016, 2016, bcr2016214582.	0.5	5

#	Article	IF	Citations
91	Toll-like receptors and cutaneous melanoma. Oncology Letters, 2016, 12, 3655-3661.	1.8	5
92	Interaction between Merkel cell carcinoma and the immune system: Pathogenetic and therapeutic implications. Molecular and Clinical Oncology, 2017, 7, 729-732.	1.0	5
93	Reflectance Confocal Microscopy in Evaluating Skin Cancer: A Clinicians's Perspective. Frontiers in Oncology, 2019, 9, 1457.	2.8	5
94	Biochip detection of BP180 autoantibodies in blister fluid for the serodiagnosis of bullous pemphigoid. Medicine (United States), 2019, 98, e14514.	1.0	5
95	Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer. In Vivo, 2020, 34, 441-445.	1.3	5
96	Primary Cutaneous B-Cell Lymphomas in Patients With Impaired Immunity. Frontiers in Oncology, 2020, 10, 1296.	2.8	5
97	Melanoma Inhibitory Activity (MIA) Is Able to Induce Vitiligo-Like Depigmentation in an in vivo Mouse Model by Direct Injection in the Tail. Frontiers in Medicine, 2020, 7, 430.	2.6	5
98	Atrophic pityriasis versicolor occurring in a patient with Sjögren's syndrome. BMJ Case Reports, 2017, 2017, bcr2016218108.	0.5	5
99	Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α. Melanoma Research, 2012, 22, 284-285.	1.2	4
100	Small-molecule-based immunotherapy for immunologically mediated skin conditions. Immunotherapy, 2020, 12, 417-429.	2.0	4
101	Diagnostic Workup of Primary Cutaneous B Cell Lymphomas: A Clinician's Approach. Frontiers in Oncology, 2020, 10, 988.	2.8	4
102	Italian expertâ€based recommendations on the use of photo(chemo)therapy in the management of mycosis fungoides: Results of an eâ€Delphi consensus. Photodermatology Photoimmunology and Photomedicine, 2021, 37, 334-342.	1.5	4
103	Association between melanoma and exposure to sex hormones in puberty: A possible window of susceptibility (Review). Molecular and Clinical Oncology, 2021, 14, 66.	1.0	4
104	Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study. Frontiers in Oncology, 2021, 11, 627527.	2.8	4
105	Case Report: Paradoxical acrodermatitis of Hallopeau-like eruption following anti-IL-17 therapy. F1000Research, 2019, 8, 336.	1.6	4
106	Is SÃ $\otimes$ zary syndrome a true primary cutaneous lymphoma?. International Journal of Dermatology, 2008, 47, 1195-1196.	1.0	3
107	Excess of melanocytic nevi in a patient treated with natalizumab for multiple sclerosis. European Journal of Dermatology, 2012, 22, 416-417.	0.6	3
108	Psoriasis induced by thalidomide in a patient with multiple myeloma. BMJ Case Reports, 2014, 2014, bcr2014204469-bcr2014204469.	0.5	3

#	Article	IF	Citations
109	A Monocentric Retrospective Observational Study of Comorbidities in Patients Affected by Autoimmune Bullous Diseases. In Vivo, 2020, 34, 2113-2118.	1.3	3
110	Complete remission of primary cutaneous anaplastic large cell lymphoma after a short course of brentuximab vedotin. Molecular and Clinical Oncology, 2021, 14, 121.	1.0	3
111	Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia. Annals of Medicine, 2022, 54, 869-874.	3.8	3
112	Absent or low expression of T-cell receptor ζ-chain in T cells infiltrating human pathological skin conditions. Archives of Dermatological Research, 2002, 294, 380-382.	1.9	2
113	TNF blockade and cutaneous lupus erythematosus: where do we stand and where are we going?. Immunotherapy, 2013, 5, 791-794.	2.0	2
114	Recent advances in localized immunotherapy of skin cancers. Immunotherapy, 2019, 11, 443-456.	2.0	2
115	Topical imiquimod-induced linear IgA bullous dermatosis. BMJ Case Reports, 2019, 12, e230037.	0.5	2
116	Programmed cell death-1 rs2227981 polymorphism in patients with autoimmune skin blistering disorders: A pilot study. Meta Gene, 2020, 26, 100793.	0.6	2
117	Bullous pemphigoid and renal graft rejection: is there a causative link?. European Journal of Dermatology, 2020, 30, 441-442.	0.6	2
118	How to Deal With Post-viral Cutaneous Eruptions in the Era of Coronavirus Infection. Frontiers in Medicine, 2020, 7, 224.	2.6	2
119	Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. Frontiers in Medicine, 2021, 8, 570921.	2.6	2
120	Melanoma in Adolescents and Young Adults: Evaluation of the Characteristics, Treatment Strategies, and Prognostic Factors in a Monocentric Retrospective Study. Frontiers in Oncology, 2021, 11, 725523.	2.8	2
121	Radiodermatitis after spinal arteriovenous fistula embolisation. BMJ Case Reports, 2016, 2016, bcr2016214384.	0.5	2
122	Eczematous, Pruritic, Brownish Plaque of the Nipple and Areola: A Quiz. Acta Dermato-Venereologica, 2019, 99, 1317-1318.	1.3	2
123	The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. Clinical and Experimental Rheumatology, 2021, 39, 1099-1107.	0.8	2
124	Trauma of Peripheral Innervation Impairs Content of Epidermal Langerhans Cells. Diagnostics, 2022, 12, 567.	2.6	2
125	In vitro Assessment of Solar Filters for Erythropoietic Protoporphyria in the Action Spectrum of Protoporphyrin IX. Frontiers in Medicine, 2021, 8, 796884.	2.6	2
126	Effects of TNF-alpha inhibitors on the number of epidermal Langerhans cells in uninvolved skin of psoriatic patients: A pilot study. Acta Histochemica, 2013, 115, 767-769.	1.8	1

#	Article	IF	CITATIONS
127	Osteoporotic vertebral fracture caused by topical corticosteroid abuse: A case report. Experimental and Therapeutic Medicine, 2019, 18, 2746-2748.	1.8	1
128	Immunomodulation in Cutaneous T Cell Lymphoma. Frontiers in Oncology, 2019, 9, 1025.	2.8	1
129	Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma. European Journal of Dermatology, 2021, 31, 99-100.	0.6	1
130	A rare case of earlyâ€onset lymphomatoid papulosis refractory to brentuximab vedotin. Dermatologic Therapy, 2021, 34, e14943.	1.7	1
131	$\hat{I}^3\hat{I}^*T$ cells as potential contributors to the progression of parapsoriasis to mycosis fungoides. Molecular Medicine Reports, 2008, 1, 485-8.	2.4	1
132	In situ expression of LAT (linker for activation of T cells) in pathological human skin with T-lymphoid infiltrate. Archives of Dermatological Research, 2004, 296, 231-234.	1.9	0
133	The role of $\hat{I}^{\hat{I}}$ T cells in human cutaneous oncology. Expert Review of Dermatology, 2006, 1, 293-301.	0.3	0
134	Analysis of immunoglobulin variable kappa gene mutations in cutaneous B-cell lymphoma. Journal of Dermatological Science, 2007, 47, 248-252.	1.9	0
135	Clinical tip: use of a manual dermatoscope with a compact digital camera in a pigmented lesion clinic. Skin Research and Technology, 2009, 15, 511-513.	1.6	0
136	Rejection-mediated Regression of Melanocytic Naevi in an Immunosuppressed Organ Transplant Recipient. Acta Dermato-Venereologica, 2014, 94, 733-734.	1.3	0
137	Exacerbation of a Primary Follicular Centre Cutaneous B-cell Lymphoma during Pregnancy and Resolution to Anetoderma After Delivery. Acta Dermato-Venereologica, 2014, 96, 828-9.	1.3	0
138	Multiple Autoimmune Skin Manifestations in a Patient with Crohn's Disease Treated with a Tumor Necrosis Factor-Alpha Blocker. Annals of Dermatology, 2015, 27, 612.	0.9	0
139	Livedoid eruption in a patient affected by T-γδ large granular lymphocyte leukaemia. BMJ Case Reports, 2017, 2017, bcr-2017-220051.	0.5	0
140	A Case of Angioinvasive Cutaneous Anaplastic Large Cell Lymphoma Completely Regressed After Low-dose Systemic Methotrexate. Acta Dermato-Venereologica, 2017, 97, 281-282.	1.3	0
141	Comorbidities in Autoimmune Skin Diseases. JAMA Dermatology, 2018, 154, 264.	4.1	0
142	Small molecule inhibitors for cutaneous T-cell lymphomas. Expert Opinion on Orphan Drugs, 2018, 6, 345-350.	0.8	0
143	PD-1 gene rs2227981 (PD-1.5) polymorphism analysis in patients with systemic sclerosis. Gene Reports, 2020, 20, 100776.	0.8	0
144	Editorial: Cutaneous B-Cell Lymphomas. Frontiers in Oncology, 2020, 10, 619709.	2.8	0

#	Article	IF	CITATIONS
145	Skin cancers in Italian lung transplant recipients: Incidence and risk factors analysis. Dermatologic Therapy, 2021, 34, e14749.	1.7	0
146	Management of PD-1/PD-L1 blockade immune-related skin toxicities: perspectives and issues. Immunotherapy, 2021, 13, 795-798.	2.0	0
147	Analysis of p53 polymorphisms in individuals with multiple melanocytic nevi. European Journal of Dermatology, 2013, 23, 280-281.	0.6	0
148	Pustular eruption associated with granulocyte colony-stimulating factor treatment. Italian Journal of Dermatology and Venereology, 2018, 153, 276-277.	0.2	0
149	Near-infrared photoimmunotherapy for the treatment of skin disorders. Expert Opinion on Biological Therapy, 2022, 22, 509-517.	3.1	0
150	Response to "change in dermoscopic pattern of naevi in children―by Scope et al. Acta Dermato-Venereologica, 2014, 94, 121-2.	1.3	0
151	Leukocytoclastic vasculitis associated with multifocal sensory neuropathy responsive to intravenous immunoglobulins: a case report. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2021, 38, e2021022.	0.2	0
152	Altitude Effect on Cutaneous Melanoma Epidemiology in the Veneto Region (Northern Italy): A Pilot Study. Life, 2022, 12, 745.	2.4	0